Trump Approves Plan to Oust FDA Chief Makary Amid Vaping, Drug and Abortion Disputes

President Donald Trump has signed off on a plan to fire Food and Drug Administration Commissioner Marty Makary, according to multiple reports citing administration sources, exposing the sharp tensions within his own health agenda barely a year into his second term. The move, first reported by The Wall Street Journal and confirmed across outlets including The New York Times and CNN, stems from Makary's refusal to rubber-stamp flavored vaping products that experts say target children and his measured approach to reproductive health medications that enraged anti-abortion activists.

Makary, a Johns Hopkins surgeon who gained prominence criticizing COVID-era public health policies, was confirmed in March 2025 as a bridge between the Make America Healthy Again movement led by Health Secretary Robert F. Kennedy Jr. and the broader Trump administration. He positioned himself as a defender of rigorous science, promising to strip politics from FDA decisions, confront Big Pharma and Big Food, and restore public trust in medicine at a time when confidence in those institutions sits at historic lows. In a recent interview with The Daily Wire, Makary insisted his agency was committed to "gold standard science" on everything from vaccines to food additives, including launching a detailed safety study on the abortion drug mifepristone rather than rushing politically motivated restrictions.

That independence proved intolerable. The breaking point came over fruit-flavored vapes from Los Angeles manufacturer Glas. Makary initially blocked approval of blueberry, mango and menthol varieties, citing clear evidence that such appealing flavors drive uptake among teenagers and underage users. Trump personally intervened, pressuring the agency until the products were eventually authorized. The episode directly undercut Trump's campaign rhetoric about "saving vaping" and his scramble to recapture young voters. Recent polling shows the president with an abysmal 24 percent approval rating among Gen Z, erasing nearly all the inroads he made with that cohort in 2024.

Anti-abortion groups piled on. Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, has demanded Makary's head since December after the FDA approved a generic version of mifepristone, the medication used in combination with misoprostol for medical abortions. The drug has been safely used in the United States for twenty-five years. Dannenfelser called the approval "reckless" and "unconscionable," claiming it undermined state-level abortion bans post-Dobbs. Former Senator Rick Santorum joined the chorus, bizarrely accusing Makary of installing "anti-Trump leftists" at the FDA who supposedly damaged innovation. White House officials are now scheduled to meet with these same activists, signaling that ideological purity tests now dictate personnel decisions at the nation's top regulatory agency.

The conflicts extended beyond vaping and abortion. Biotech and pharmaceutical companies complained about Makary's rejection of certain new drug applications, while internal turnover at the FDA continued at a rapid clip. Makary had tried to thread a difficult needle, publicly aligning with MAHA goals like improving the food supply, speeding certain approvals, and attracting more clinical trials to the United States. He appeared frequently on television and podcasts touting these efforts. Yet his willingness to slow down youth-oriented nicotine products and insist on evidence before further restricting reproductive medications ultimately made him enemies in an administration that rewards loyalty over public health data.

Administration officials briefed on the matter told reporters the ouster plan is not yet final and could shift, consistent with Trump's well-documented habit of changing his mind after persuasive appeals. Makary has reportedly talked the president out of firing him before. A White House spokesman offered the standard defensive statement, claiming the Trump administration is the "most experienced and talented" in history and remains focused on "historic victories" for the American people. Makary himself had no immediate comment.

This brewing dismissal reveals the contradictions at the heart of Trump's health policy. The MAHA banner promises to make America healthier by taking on corporate capture of food and medicine. Yet here the president appears ready to jettison one of its most visible advocates for the crime of worrying that mango-flavored nicotine will hook another generation of adolescents. At the same time, pressure from anti-abortion groups seeks to override twenty-five years of safety data on mifepristone in favor of making a long-approved medication harder and more expensive to obtain.

The FDA has already lost thousands of staff members since Trump returned to office. Further politicizing its leadership will only accelerate the erosion of expertise and public confidence. Makary's departure would leave the agency even more vulnerable to industry influence and ideological interference at a moment when issues from chronic disease to emerging treatments demand careful, evidence-driven oversight rather than poll-driven or lobbyist-driven decisions.

For an administration that campaigned on draining the swamp and restoring trust in science, firing a commissioner for attempting to shield children from addictive flavored vapes and insisting on proper studies before restricting women's access to safe medication sends the opposite message. It suggests that in Trump's Washington, protecting tobacco industry profits and appeasing single-issue activists rank higher than the health of young people or the integrity of regulatory science. The decision, should it stand, risks setting back both the MAHA agenda and the FDA's already fragile credibility for years to come.